Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Medpace (MEDP)

Medpace Q3 revenue rises 23.7% to $659.9 million; diluted EPS $3.86 vs $3.01

Positive Impact 3 of 5 earnings Written later

Medpace reported third-quarter 2025 revenue of $659.9 million, up 23.7% from a year earlier, and GAAP diluted earnings per share of $3.86, up from $3.01. Net income margin slipped to 16.8% from 18.1%, and the filing gives 2025 revenue and EPS forecasts but no prior forecast to compare them with.

Key points

  • Q3 2025 revenue $659.9 million, up 23.7% from $533.3 million; EBITDA $148.4 million, up 24.9%
  • Q3 net new business awards $789.6 million, up 47.9%, for a book-to-bill ratio of 1.20x
  • Q3 GAAP net income $111.1 million, or $3.86 per diluted share, vs $96.4 million, or $3.01, a year earlier
  • 2025 guidance: revenue $2.480 billion to $2.530 billion and GAAP diluted EPS $14.60 to $14.86

The filing

CompanyMedpace (MEDP)
Form8-K, current report
Filed with the SECOct 22, 2025, 4:15 PM ET
Accession number0001668397-25-000108

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 22, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.